Press

Novamind Divests Non-Core Retreat Investment

Aug 11 • 3 min read

Quick Take: Novamind has announced the completion of its investment in the Synthesis Institute, a psychedelic retreat and practitioner program located in the Netherlands. Novamind Inc. (CSE: NM, OTC: NVMDF) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, today announced that it has completed the sale of the Company’s investment…

MYND Life Sciences Announces DTC Eligibility

Aug 11 • 2 min read

Quick Take: MYND Life Sciences is now eligible for Depository Trust Company services in relation to the Company’s listing on the OTC. MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND”) is a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals and vaccines is pleased to announce that it is now eligible…

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

Aug 10 • 5 min read

Quick Take: Revive provides an update on their psychedelic product development pipeline. One key component of their research pipeline is the research of the use of psilocybin to treat traumatic brain injury and stroke. Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for…

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

Aug 10 • 4 min read

Quick Take: MindMed has appointed Dr. Robert Dworkin, a professor with over 35 years of conducting clinical research on pain, to its scientific advisory board. MindMed (NASDAQ: MNMD) (NEO: MMED), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years…

Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology

Aug 9 • 4 min read

Quick Take: Ketamine one has partnered with a virtual reality company to begin its scent-based VR therapy platform. KetamineOne Capital Limited (NEO: MEDI), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce it has signed an exclusive agreement for the use of virtual…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441